CGT

70개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved70 programs
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTStandard DatabasestaleGenetix Biotherapeutics Inc.Phase 2

Lentiviral vector transduced CD34+ cells (Lentiviral vector transduced CD34+ cells)

P47-Phox, Deficiency of · CD3

#CD3#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 50Status Active
CGTStandard DatabasestaleGenetix Biotherapeutics Inc.Phase 2

transduced CD34+ hematopoietic stem cell (transduced CD34+ hematopoietic stem cell)

Metachromatic Leukodystrophy; Adrenoleukodystrophy · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 48Status Active
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 1

CD30+ CAR T-cells (CD30+ CAR T-cells)

Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 32Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleIntrexon CorporationPhase 1

CD33-CAR-T Cell Infusion (CD33-CAR-T Cell Infusion)

Hematopoietic/Lymphoid Cancer; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 20Status Discontinued
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Adult T-Cell Lymphoma/Leukaemia; Anaplastic Large Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 13Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 7Status Recruiting
CGTLimited DatastaleHangzhou Qihan Biotech Co., Ltd.Phase 1

CD33 CAR-NK cell (CD33 CAR-NK cell)

AML, Adult; Minimal Residual Disease · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 7Status Active
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 2

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 6Status Recruiting
CGTStandard DatabasestaleGenethonPhase 2

Autologous CD34+ cells transduced with WASP lentiviral vector (Autologous CD34+ cells transduced with WASP lentiviral vector)

Wiskott-Aldrich Syndrome · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 5Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

B Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Leukemia, Myeloid, Acute · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTStandard DatabasestaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleGenetix Biotherapeutics Inc.Phase 2

Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a (Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a)

Sickle Cell Disease · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting

1 / 4 pages

← PreviousNext →